Subject index / 639

Neale, M.L., 250 Nesbitt, A.M., 361 Norga, K., 231 North, R.J., 398

Onaya, T., 345 Opdenakker, G., 231 Osbom, L., 372 Oseko, F., 609 Osrath, S., 92 Otterness, I.G., 277,333

Paul, W., 224 Peppard, J.V., 543 Peterson, P.K., 292 Pinsky, M.R., 1 Poot, M., 593 Preiser, J.-C., 1 Prescott, A.R., 299 Princler, G.L., 627 Proost, P., 231

Qin, Z., 72

Raabe, T., 72 Rakhmilevich, A.L., 398 Ramshaw, I., 92 Rasmussen, A.K., 125 Ray, K., 42 Repine, J.E., 189 Revel, M., 83 Richards, C.D., 269 Richter, G., 72 Rollins, P., 42 Romero, R., 155 Rosandich, M.E., 189 Rot, A., 21 Ruben, L. N., 28 Ruby, J., 92

Sadler, H., 42 Sakata, Y., 199 Sakihama, T., 345 Saklatvala, J., 269 Sakurai, S., 155 Sanderson, C.J., 339, 350 Santhanam, U., 155 Schall, T.J., 165 Schmartz, D., 1 Schmidt, J.A., 240 Schrader, J.W., 414 Schroder, J.-M., 322 Schulze-Osthoff, K., 284 Schwabe, M., 627 Sebald, W., 1,593 Sehgal, P.B., 155,204,212 Seymour, P.A., 333 Shaw, J.E., 204 Simon, S.R., 576 Smithers, N., 42 Sofia, R.D., 568 Solari, R., 42 Stall, A.M., 551 Sticherling, M., 322 Strassmann, G., 421 Strath, M., 339 Strober, W., 224 Suzuki, K., 584 Svenson, M., 125

Tager, J.M., 54 Takacs, L., 598 Tamm, I., 212 Tasaka, K., 345 Taylor, K.M., 250 Ten, R.M., 350 Thomas, K., 292 Thompson, D., 619 Thompson, N., 42

Thompson, R.C., 246 Thorpe, R., 562 Tsang, M., 292 Tscherning, T., 35 Tuin, K., 54

Uberla, K., 72

Vaiman, D., 83 Van Bladel, S., 149 Van Damme, J., 195,231,311 Van der Linden, P., 1 Van Ranst, M., 231 Van Roy, F., 284 Vandekerckhove, F., 231 Vanden Bussche, P., 1 Viguet, H., 155 Vincent, J.-L., 1

Wadhwa, M., 562 Wahl, L.M., 98 Wahl, S.M., 98 Warn, R.M., 299 Watson, C., 224 Weiler, D.A., 350 Weissman, A.M., 598 Whither, J.T., 12, 619 White, C.W., 189 Witham, S., 42 Wolff, SM., 568 Woo, P., 380

Yin, L., 5

Zabriskie, J.B., 204 Zhang, L., 372 Ziltener, H.J., 414 Zlotnik, A., 366

SUBJECT INDEX

Acid glycoprotein, inflammation and, 619-625 insulin and, 619-625

Acquired immunodeficiency syndrome (AIDS), HIV role in, 531- 538,532f

tau-Actin, temperature effects and, 389-396 Actin fibers, cell motility and, 299-309

epithelial cell, 299-309 scatter factor effects on, 299-309

Actinomycin D, IgA production abolished by, 107-115 Adenosine monophosphate (AMP), IL-1 stimulation and, 42-51

IL-2 secretion blocked by, 42-51 Adenylate synthetase gene, IFN responsive sequence of, 83-90 Albumin, inflammation and, 619-625

insulin and, 619-625 Amniotic fluid, IL-6 levels in, 155-162 Amyloid A, gene transcription and, 380-387

IL-l mediation and, 380-387 Angiotensin, IL-1 effects and, 131-133

mesangial cells and, 131-13 Antichymotrypsin, inflammation and, 619-625

insulin and, 619-625 Antigen-presenting cells, IL-10 effects and, 366-370

Antigens, recombinant, immunoassay error and, 562-566 Antitrypsin, inflammation and, 619-625

insulin and, 619-625 Appetite, IL-lo and, 333-337 Arachadonic acid, IFN-7 effects and, 98-105 Arterial pressure, IL-6 effects and, l-3,2t Arthritis, anti-CD4 therapy in, 266-267

IFN-(w inhibition of, 98-105 IFN-l3 inhibition of, 98-105 IFN-y and, 266-267 IL-1 induction of, 246-249 IL-1 production and, 277-283 IL-1B and, 266-267 IL-2 and, 266-267 MCP-1 role in, 178-179 MIP-la role in, 178-179 RANTES role in, 178-179 tenidap effects and, 277-283 TNF-(Y and, 266-267

Atherosclerosis, MCP-1 role in, 178 MIP-lrw role in, 178 MIP-lp role in, 178,178(f) RANTES role in, 178

640 / Subject index CYTOKINE, Vol. 3, No. 6 (November 1991: 638648)

Autoimmune disease, IL-6 in, 345-348 thyroid and, 345-348 TNF-a role in, 551-560

B cells, blastogenesis inhibitor for, 609-617 differentiation of, 107-115 germinal center, 107-115 growth factor for. See Interleukin-5 (IL-5). IgA production by, 107-115 IL-2 effects on, 584-591 IL-2Ra expression by, 584-591 IL-2RB expression by, 584-591 IL-4 effects on, 584-591 IL-5 receptor on, 339-333 IL-6 and, effects, 17-20

glycosylation, 204-210 induction, 107-115 receptor number, 17-20

IL-10 effects in, 366-370 lymphoblastoid, 609-617,627-633 memory, 107-115 mucosal sites and, 107-115 non-germinal center, 107-115 plasma cell transition of, 107-115 proliferation inhibitor for, 609-617 staphylococcal stimulation of, 98-105 thymus-replacing factor and, 28-33,30t

Baculovirus, IL-5 production method using, 224-229 Behavioral effects, IL-101 causing, 333-337

piroxicam and, 333-337 prostaglandins and, 333-337

Binding, competitive inhibition of, 407-412 Blood cell count, IL-6 and, 1-3,2(t), 199-202 Bone marrow, progenitor cells of, 60-69

proliferation measurement in, 426 Bone resorption, GM-CSF and, 421-426

IL-@ and, 421-426 enhancement, 141-147 M-CSF and, 421-426 parathyroid hormone and, 421-426 prostaglandin synthesis and, 421-426 vitamin D and, 421-426

Bradykinin, bone Ca release and, 141-147 BromodeoquridineiHoechst test, 593-597

Calcium, bone resorption and, 141-147,421-426 Calcium channels, IL-1 effect on, 131-133

mesangial cells and, 131-133 Calcium ion, NF-KB factor and, 257-264

T cell and, 257-264 Carcinoma cells, IL-6 effect on, 212-222

morphology conversion in, 212-222 motility increase in, 212-222

Cardiac output, IL-6 effects and, 1-3,2(t) Cartilage, inflammation effects on, 246-249

proteoglycan loss from, 246-249 Cathepsin G, CTAP-III acted on by, 311-320

NAP-2 production role of, 311-320 C-C molecules, definition of, 165-167 CD4, antibody to, 266-267

arthritis and, 266-267 HIV expression and, 531-538,532f T cell y8 receptors and, 598-606

CD8, T cell y8 receptors and, 598-606 Cell blot assay, 185t, 187

Cell morphology conversion, carcinoma cells and, 212-222 cytoskeleton in, 299-309 epithelial, 299-309 IL-6 and, 212-222 motility cytokines and, 299-309

Cell motility, carcinoma cells and, 212-222 chemotaxis and, 21-26 IL-6 increase of, 212-222 motility cytokines and, 299-309

Cell wall fragments, arthritis produced by, 98-105 Chemotaxis, IL-8 role in, 21-26

NAP-l role in, 21-26 Chicken, IL-8 of, 21-26 Chimeric gene analysis, 185(t) Chloramphenicol acetyltransferase, amyloid A gene and, 380-387 Cholera toxin, IL-1 stimulation and, 42-51

IL-2 secretion and, 42-51 Chromosome 17, I-309 gene and, 172(f)

MCP-1 gene and, 172(f) MIP-la gene and, 172(f) MIP-1B gene and, 172(f)

Chronic fatigue syndrome, cytokine role in, 292-293 IL-1B in, 292-297 IL-2 in, 292-297 IL-4 in, 292-297 IL-6 in, 292-297 immunoglobulins in, 292-297 pathogenesis of, 292-293 TGF-B increased in, 292-297 TNF-a in, 292-297

Colony-stimulating factor (CSF). See also Grunulocyte-macrophage CSF (GM-CSF);Macrophage CSF (GM-CSF).

IL-3 as, 60 myeloid cell response to, 60-69

Concanavalin A (Con A), gelatinase induction by, 231-238 thymocytes treated with, 598-606

Conditioned media, 67-68 thymoma cells used in, 350-358

Connective tissue-activating peptide- (CTAP-III), NAP-2 precur- sor role of, 311-320

platelet derivation of, 311-320 protease action on, 311-320

Copper, IL-6 effects and, 199-202 Cross-reactivity, species, IL-8 and, 21-26 CSF. See Colony-stimulatingfactor (CSF). C-X-C molecules, definition of, 165-167, 166(f) Cyclosporin A, NAP-l secretion not affected by, 311-320 Cytokine synthesis inhibitory factor. See Interleukin-10 (IL-IO). Cytokines, book review and, 360

C-C branch of, 165-180,168(f) chronic fatigue syndrome and, 292-297 C-X-C branch of, 165-167 cytoskeleton effects of, 299 detection methodology for, 184-187 HIV expression regulated by, 531-538,532(f) intracellular measurement of, 184-187 islet cell effects of, 117-123 lithium chloride potentiation and, 284-290 motility factors as, 299 PF4 superfamily of, 165-180 RANTESiSIS family of, 165-180 single-cell measurement of, 184-187

Cytoskeleton, actin fibers of, 299-309 microtubules of, 299-309 motility factor effects on, 299-309 scatter factor effects on, 299-309

Subject index / 641

Cytotoxic T cells. See also Helper T cells; T cells. IL-2 antibody and, 54-58 immunosuppression and, 5-10,6-9 inhibition of proliferation of, 54-58 self-impairment of, 28-33,30t

Cytotoxicity, IL-1 and, 117-123 islet cells and, 117-123

Dexamethasone, acute phase proteins and, 619-625 inflammation and, 619-625 insulin with, 619-625 TNF release not affected by, 568-574

Diabetes, IL-l role in, 117-123 insulitis and, 117-123 islet cells and, 117-123

DNA, carcinoma cells synthesis of, 212-222 IL-5 gene and, 72-80 IL-6 and, 269-275 IL-6 suppression and, 212-222 polymerase chain reaction and, 72-80 retroviral gene transfer and, 72-80

Dog, IL-8 of, 21-26 Dot blot analysis, 115 Drinking behavior, rat, IL-lo and, 333-337

Elastase, proteinase inhibitor complex with, 12 sepsis and, 12-16,13

Elastase-alpha, proteinase inhibitor, pancreatitis and, 12-16,13 sepsis and, 12-16, I3

ELISPOT assay, 185(t), 187 Endotoxins. See Lipopolysaccharides (LPS). Enhancer domain, HIV transcription and, 535-536,536(f) Enzymes, proteolytic, 231-238 Eosinophils, differentiation of, 350-358

factor for, 60-69 IL-5 and, effects, 350-358

regulation, 60-69 IL-SR on, 339-333 peroxidase activity of, 350-358 prolonged survival of, 350-358

Epidermal growth factor (EGF), carcinoma cell morphology and, 212-222

IL-6 not induced by, 269-275 Epithelial cells, cytoskeleton of, 299-309

IgA secretion and, 543-549 MHC antigens of, 543-549 motility cytokines and, 299-309 scatter factor effects on, 299-309 secretory component and, 543-549 TGF-l3 effects in, 543-549

Epstein-Barr virus gene, IL-10 homology with, 368-369 Extracellular matrix, TNF resistance and, 250-255

tumor cells and, 250-255

F factors, IFN effects and, 83-90 IL-6 effects and, 83-90 myeloleukemic cells and, 83-90

Fatigue. See Chronic fatigue syndrome. Fever. See also Temperature.

cerebroventricular injection and, 199-202 hypothalamus and, 195-197 IL-1 causing, 195-197 IL-6 causing, 195-197,199-202 serum metals and, 199-202

Fibrinogen, IL-6 effect on, 199-202 inflammation and, 619-625 insulin and, 619-625

Fibroblast growth factor (FGF), carcinoma cell morphology and, 212-222

Fibroblasts, EGF non-effect on, 269-275 IFN-y effects and, 98-105 IL-l stimulation of, 42-51 IL-6 and, glycosylation, 204-210

production, 269-275 synovial, 98-105

porcine, 269-275 TGF-l3 non-effect on, 269-275 TNF effects on, 269-275

Fibronectin, TNF resistance and, 250-255 tumor cells and, 250-255

Filaments, keratin, cell motility and, 299-309 Fluorescein, streptavidin and, IL-3 binding marked by, 414-419 Fluorescence, Hoechst dye and, 593 Fluorescence immunoassay, receptor quantification with, 17-20

single-cell cytokine detection by, 185t Flurbiprofen, bone Ca release and, 141-147 Formylated peptides, chemotaxis and, 21-26 c-fos gene, IL-1 effects and, 372-378

TNF-ct effects and, 372-378 Frog, metamorphic spleen of, 28-33,30(t)

T cell circumvention in, 28-33,30(t) Fusion proteins. See Protein hybrids.

Gangliosides, TNF resistance and, 250-255 tumor cells and, 250-255

Gastrointestinal tract, B cells of, 107-115 Peyer’s patches of, 107-115

Gelatinase, IL-1B induction of, 231-238 monocyte production of, 231-238 phorbol ester induction of, 231-238 purification of, 231-238

Germinal centers, Peyer’s patches and, 107-115 Glycosylation, cell species differences in, 204-210

IL-6 and, 204-210 Goat, IL-8 of, 21-26 Granulocyte CSF (G-CSF), IL-3 as, 60

myeloid cell response to, 60-69 Granulocyte-macrophage CSF (GM-CSF). See also Mucrophage

CSF (M-CSF). antibody probe for, 414-419 bone resorption and, 421-426 HIV expression and, 531-538,532(f) lithium chloride potentiation and, 284-290 myeloid cell response to, 60-69 prostaglandin synthesis and, 421-426 receptor binding of, 414-419

Growth inhibition, IL-1 and, 131-133 mesangial cells and, 131-133

Guinea-pig, IL-8 of, 21-26

HC-14,170-180 amino acid sequence of, 168(f) cells expressing, 175(t) isolation of, 167(f)

Helper T cells. See also Cytotoxic T cells; Tcells. B cell transition and, 107-115 IL-10 inhibition of, 366-370 immunosuppression and, S-10 plasma cell formation and, 107-115

Hemagglutinin gene, IL-1 effects and, 92-96 immune response factors and, 92-96 viral vector for, 92-96

642 I Subject index CYTOKINE, Vol. 3, No. 6 (November 1991: 638648)

Hemodynamics, IL-6 effects and, 1-3,2(t) (Continued) Hemodynamics, IL-6 effects and, 1-3,2(t) Hemoglobin, IL-6 and, 1-3,2(t) Hepatocytes, acute phase proteins from, 619-625

IL-6 effects in, 149-153 inflammation role of, 619-625 insulin effects in, 619-625 TNF receptor expression by, 149-153

Hoechst fluorescence, 593 Human immunodeficiency virus (HIV), cytokine regulation of,

531-538,532(f) enhancer domain of, 372-378,535-536,536(f) expression of, 531-538,532(f) IL-l effects and, 372-378 immunosuppressive mechanisms and, 531-538,532(f) long terminal repeat of, 535-536,536(f) NF-KB and, 372-378 phorbol ester effects and, 372-378 TNF-(Y effects and, 372-378 transcription of, 531-538,532(f)

Hybrid proteins. See Proteins, hybrid. Hybridoma cells, IL-la antibodies and, 134-139

IL-@ effects on, 284-290 lithium chloride effects and, 284-290 spleen-myeloma, 134-139 TNF effects on, 284-290

Hypothalamus, fever and, 195-197 IL-l injected in, 195-197 IL-6 injected in, 195-197

Hypoxia, IL-la increase and, 189-192 IL-l@ increase and, 189-192 TNF increase and, 189-192

Immunization, high-dose intravenous, 5-10 minor histocompatibility in, 5-10

Immunoassay, erroneous results in, 562-566 fluorescence, IL-6R quantification with, 17-20

receptor quantification with, 17-20 single-cell cytokine detection by, 185(t)

IL-3 and, 562-566 IL-4 and, 562-566 monoclonal antibodies in, 562-566 recombinant antigens and, 562-566

Immunoglobulins, A, 107-115,543-549 B cells and, inhibition, 609-617

production, 107-115 secretion, 17-26

chronic fatigue syndrome and, 292-297 epithelial cell secretion of, 543-549 G,, 54-58 IL-1B stimulation and, 141-147 IL-6 regulation of, 107-115 IL-6R effects and, 17-26 M, 17-26 mucosal secretion of, 543-549 protein hybrids and, 134-139 spleen cell production of, 141-147 TGF-B effects and, 543-549

Immunostaining, 185(t), 186 Immunosuppression, HIV and, 531-538,532(f)

IFN-ol role in, 98-105 IFN-B role in, 98-105 IFN-y role in, 98-105 IL-2 and, 5-10 IL-3 and, 5-10 minor histocompatibility antigens in, 5-10

Immunosuppression, HIV and (Continued) T cells in, 5-10

circumvention and, 28-33, 30(t) thymus-replacing factor and, 28-33,30(t)

Indomethacin, prostaglandin response and, 141-147 Inflammation. See also Sepsis.

acute phase proteins in, 619-625 dexamethasone in, 619-625 IL-6 and, 619-625 IL-8 role in, 21-26 insulin role in, 619-625 joints and, 246-249

Inhibitors, IL-10 as, 366-370 Insect cells, IL-6 glycosylation and, 204-210 Insulin, acute phase proteins and, 619-625

cytokine effects and, 117-123 dexamethasone inhibited by, 619-625 diabetes and, 117-123 IL-1 effects and, 117-123 inflammation modulated by, 619-625 islet cell damage and, 117-123 lymphotoxin effects and, 117-123 secretion of, 117-123

Insulin-like growth factor (IGF), carcinoma cells and, 212-222 Interferon (IFN), HIV and, 531-538,532(f)

IL-6 synergism with, 83-90 insulin secretion and, 117-123 islet cell effects of, 117-123 myeloleukemic cell response to, 83-90

Interferon-d (IFN-(?I), adenylate synthetase gene and, 83-90 arthritis inhibition by, 98-105 B lymphoblastoid cells and, 627-633 endotoxin-induced, 398-405 IL-6 synergism with, 83-90 immunosuppression and, 98-105 myeloleukemic cell reponse to, 83-90 receptor complexes for, 627-633 tumor cell implantation and, 398-405

Interferon-B (IFN-B), adenylate synthetase gene and, 83-90 arthritis inhibition by, 98-105 endotoxin-induced, 398-405 IL-6 synergism with, 83-90 immunosuppression and, 98-105 myeloleukemic cell reponse to, 83-90 tumor cell implantation and, 398-405

Interferon-y (IFN-y), adenylate synthetase gene and, 83-90 arachidonic acid metabolism and, 98-105 arthritis and, 266-267

inhibition and, 98-105 fibroblasts affected by, 98-105 IL-l fused with, 134-139 immunosuppression and, 98-105 macrophages affected by, 98-105 myeloleukemic cell response to, 83-90 prostaglandins affected by, 98-105 synovial effects of, 98-105 TNF receptor expression and, 149-153

Interferon-responsive sequence, adenylate synthetase gene and, 83-90

enhancer for, 83-90 IL-6 effect on, 83-90 leukemia cells and, 83-90 protein complexes of, 83-90

Interleukin 1 (IL-l), antibody to, 117-123 arthritis role of, 246-249 coexpressed IL-la and, 92-96 cytotoxicity of, 117-123

Subject index I 643

Interleukin 1 (IL-l), antibody to (Continued) diabetes role of, 117-123 endotoxin-induced, 398-405 fever induced by, 195-197 hepatocyte response to, 149-153 HIV enhancer and, 372-378 hypothalamus injected with, 195-197 IL-2 and, enhancer, 372-378

induction, 42-51 regulation, 389-396

immune response enhanced by, 92-96 islet cell effects of, 117-123 joint inflammation induced by, 246-249 lymphotoxin synergy with, 117-123 macrophage release of, 327-332 mesangial cell growth inhibited by, 131-133 mononuclear cell synthesis of, 568-574 NF-KB activation by, 372-378 prostaglandin regulation of, 327-332 receptor antagonist for, 246-249 septic shock role of, 568-574 serum amyloid A gene and, 380-387 signal transduction pathways of, 42-51 taurolidine inhibition of, 568-574 temperature effects and, 389-396 TNF binding and, 149-153 tumor cell implantation and, 398-405

Interleukin 1 receptor (IL-lR), antagonist for, 246-249 pertussis toxin effect on, 42-51

Interleukin lcl (IL-la), adjuvanticity of, 92-96 anorexic effects of, 333-337 behavioral effects of, 333-337 coexpressed IL-l and, 92-96 cytotoxicity of, 117-123 diabetes role of, 117-123 hypoxia potentiation of, 189-192 IFN-y fused with, 134-139 IL-6 induction by, 269-275 immune response enhanced by, 92-96 infusion of, 333-337 islet cell effects of, 117-123 myeloid cell response to, 60-69 prostaglandins with, 333-337 receptor antagonist and, 407-412 receptor for, 407-412 T-cell receptors for, 125-130 thyroid cell receptors for, 125-130 vaccinia virus encoded, 92-96

Interleukin lol (IL-la) gene, 60-69 myeloid cell expression of, 60-69 retroviral vector for, 60-69 vaccinia virus vector for, 92-96

Interleukin 16 (IL-lp), antibody to, 240-245 arthritis and, 266-267 bone resorption and, 141-147,421-426 chronic fatigue syndrome and, 292-297 cytotoxicity of, 117-123 diabetes role of, 117-123 fragment 163-171 of, 141-147 gelatinase induction by, 231-238 hybridoma cell response to, 284-290 hypoxia potentiation of, 189-192 IL-6 production enhanced by, 345-348 immunostimulatoty effect of, 141-147 islet cell effects of, 117-123 lithium chloride enhancement and, 284-290 peptide segments of, 240-245

Interleukin lp (IL-lp), antibody to (Continued) prostaglandin biosynthesis and, 141-147 protease induction by, 231-238 sarcoma cell response to, 284-290 synthetic peptides and, 240-245 TSH synergy with, 345-348

Interleukin 2 (IL-2), 5 antibody to, affinity of, 55(t)

monoclonal, 54-58 native vs. recombinant recognition by, 54-58 specificity of, 55(t) T-cell proliferation blocked by, 54-58

arthritis and, 266-267 chronic fatigue syndrome and, 292-297 HIV enhancer and, 372-378 IL-l and, effects, 372-378

induction, 42-51 regulation, 389-396

IL-4 synergism with, 593-597 immunosuppression and, 5-10 lithium chloride potentiation and, 284-290 native vs. recombinant, 54-58 radiolabeling of, 58 receptor complex with, 428-437 T cells and, up receptors, 598-606

antigen receptors, 598-606 cycling, 593-597 y6 receptors, 598-606

temperature effects and, 389-396 TNF effects and, 372-378 tyrosine kinase activity and. 428-437

Interleukin 2 receptor (IL-2R), antibody block of, 9 antibody to, 35-41 high-affinity, 584-591 IL-2 complex with, 428-437 IL-4 and, synergism, 35-41

up-regulation, 584-591 IL-5 up-regulation of, 584-591 MHC class I interactions of, 35-41 subunits of, 429 T-cell activation role of, 35-41 tyrosine kinase activity and, 428-437

Interleukin 2 receptor-o (IL-2Ra), B-cell expression of, 584-591 IL-2 effects and, 584-591 IL-4 effects and, 584-591 IL-5 up-regulation of, 584-591 lithium chloride potentiation and, 284-290 T-cell expression of, 584-591

Interleukin 2 receptor-p (IL-2Rp), B-cell expression of, 584-591 IL-2 effects and, 584-591 IL-4 effects and, 584-591 IL-5 effects and, 584-591 T-cell expression of, 584-591

Interleukin 3 (IL-3), antibody probes for, 414-419 epitopes of, 414-419 fluorescein-labeled streptavidin and, 414-419 immunoassay for, 562-566 immunosuppression and, 5-10 lithium chloride potentiation and, 284-290 myeloid cell response to, 60-69 receptor interaction of, 414-419

Interleukin 3 receptor (ILSR), T-cell activation role of, 35-41 Interleukin 4 (IL-4) chronic fatigue syndrome and, 292-297

IL-2 synergism with, 593-597 immunoassay for, 562-566 T-cell cycling stimulated by, 593-597

644 I Subject index CYTOKINE, Vol. 3, No. 6 (November 1991: 638-648)

Interleukin 4 receptor (IL-4R), antibody to, 35-41 (Continue Interleukin 4 receptor (IL-4R), antibody to, 35-41

IL-2 synergism with, 35-41 MHC class I interactions of, 35-41 T-cell activation role of, 35-41

Interleukin 5 (IL-5), baculovirus expression of, 224-229 cell proliferation and, 72-80 dependent cell lines for, 72-80 eosinophil differentiation and, 60-69,350-358 glycosylation of, 224-229 myeloid cell response to, 60-69 production method for, 224-229 purification of, 224-229 recombinant, 224-229 signal transduction pathways of, 60-69 thymoma cell production of, 350-3.58

Interleukin 5 (IL-5) gene, 72-80 coding regions of, 72-80 cDNA version of, 72-80 human, 72-80 mouse, 72-80 polymerase chain reaction and, 72-80 rat, 72-80 sequencing of, 72-80 structure of, 72-80

Interleukin 5 receptor (IL-5R), antibody to, 339-333 B cell, 339-333 eosinophilic, 339-333 high-affinity, 339-333 low-affinity, 339-333

Interleukin 6 (IL-6), adenylate synthetase gene and, 83-90 amniotic fluid and, 155-162 autoimmune disease and, 345-348 B cells and, production, 204-210

response, 107-115 carcinoma cell effects of, 212-222 cell morphology conversion and, 212-222 cell motility increase and, 212-222 cell-type differences in, 204-210 cerebroventricular injection of, 199-202 chronic fatigue syndrome and, 292-297 cDNA sequencing for, 269-275 DNA synthesis decrease and, 212-222 EGF non-induction of, 269-275 endotoxin-induced, 398-405 fetal, 155-162 fever induced by, 195-197,199-202 fibroblast and, 204-210,269-275 glycosylation differences in, 204-210 hemodynamic effects of, 1-3,2(t) HIV expression and, 531-538,532(f) hypothalamus injected with, 195-197 IFN synergism with, 83-90 IgA production and, 107-115 IL-1c~ induction of, 269-275 IL-lp enhancement of, 345-348 insect cell, 204-210 intravenous, 1-3,2(t), 199-202 lithium chloride potentiation and, 284-290 macrophage release of, 327-332 maternal, 155-162 myeloid cell and, production, 60-69

response, 60-69 myeloleukemic cell response to, 83-90 parturition rise in, 15.5-162 phorbol ester synergism with, 212-222 pig vs. human vs. mouse, 269-275

:d) Interleukin 6 (IL-6), adenylate synthetase gene and (Continued) plasma cell formation and, 107-115 pregnancy levels of, 155-162 premature rupture of membranes and, 15.5-162 prostaglandin regulation of, 327-332 TGF-p non-induction of, 269-275 thyroid cell production of, 345-348 TNF and, induction, 269-275 TNF receptor expression and, 149-153 TSH enhancement of, 345-348 tumor cell implantation and, 398-405 uterine infection and, 155-162

Interleukin 6 (IL-6) gene, retroviral vector for, 60-69 Interleukin 6 receptor (IL-6R), B-cell number of, 17-20

immunofluorescence assay for, 17-20 Interleukin 8 (IL-S), neutrophil attractant role of, 21-26

species cross-reactivity of, 21-26 Interleukin 10 (IL-lo), 366-370

cytokine synthesis inhibition by, 366-370 Epstein-Barr virus homology with, 368-369 helper T cells affected by, 366-370 mechanism of action of, 366-370 mouse vs. human, 366-370 pleiotropic activities of, 366-370 review of, 366-370

Ionomycin, NF-KB activation and, 372-378 Iron, IL-6 effect on, 199-202 Islet cells, cytokine effects in, 117-123

diabetes role of, 117-123 IL-l cytotoxicity for, 117-123 inflammation damage to, 117-123 lymphotoxin effects and, 117-123 rat vs. human, 117-123

I-309, 171-180 alternative names for, 166(t) amino acid sequence of, 168(f) cells expressing, 175(t) chromosome 17 and, 172(f) regulatory elements for, 173-174,175(t)

I-309 gene, chromosome 17 and, 172(f) structure of, 172(f)

c-&n gene, IL-l effects and, 372-378 TNF-cu effects and, 372-378

Keratin filaments, cell motility and, 299-309

Lactate, IL-6 and, 1-3,2(t) Lamina propria, B cells of, 107-115

Peyer’s patches of, 107-115 Leukemia cells, adenyIate synthetase gene in, 83-90

differentiation of, 83-90 growth factors of, 83-90 IFN effects in, 83-90 IL-6 activation and, 83-90

Limiting dilution analysis, 185(t), 186 Lipopolysaccharides (LPS). See also Sepsis; specific endotoxins.

enhanced lethality of, 398-405 gelatinase induction by, 231-238 hypoxia potentiation and, 189-192 IFN response and, 398-405 IL-l and, induction, 277-283

non-response, 398-405 IL-6 release and, 1-3,2(t), 398-405 macrophages and, priming, 327-332

response, 277-283 monocyte stimulation with, 231-238,568-574

Subject index / 645

Lipopolysaccharides (LPS) (Continued) TNF release and, 568-574 tumor cells and, 398-405

Lithium chloride, cytokine release and, 284-290 IL-lp effects potentiated by, 284-290 sarcoma cell response to, 284-290 TNF effects potentiated by, 284-290

Locomotor activity, rat, IL-lo and, 333-337 Long terminal repeat, HIV transcription and, 535-536,536(f) Lupus erythematosus, TNF-a role in, 551-560 Lymph nodes, IL-3 production in, 6 Lymphoblastoid cells, inhibitory factor from, 609-617 Lymphocytes. See B cells; Mononuclear cells; T cells. Lymphotoxin, cytokine synergy with, 117-123

IL-l synergy with, 117-123 insulin secretion and, 117-123 islet cell damage and, 117-123

Macrophage CSF (M-CSF), bone resorption and, 421-426 HIV expression and, 531-538,532(f)

Macrophage inflammatory protein-l (MIP-l), 167-180 Macrophage inflammatory protein-la (MIP-la), 167-180

alternative names for, 166(t) amino acid sequence of, 168(f) atherosclerosis role of, 178 cells expressing, 175(t), 179(f) chromosome 17 and, 172(f) isolation of, 167(f) mouse vs. human, 172(f) physiological role of, 175-180,179(f) regulatory elements for, 173-174,175(t) structure of, 172(f) T cells and, 174(f), 177(f), 179(f)

Macrophage inflammatory protein-ll3 (MIP-ll3), alternative names for, 166t

amino acid sequence of, 168(f), 169(f) atherosclerosis role of, 178, 178(f) cells expressing, 175(t), 179(f) chromosome 17 and, 172(f) isolation of, 167(f) physiological role of, 175-180,179(f) regulatory elements for, 173-174,175(t) signal sequence of, 169(f) structure of, 172(f) T cells and, 174(f), 177(f), 179(f)

Macrophages, arthritis role of, 98-105 HIV expression and, 531-538,532(f) IFN-7 effects and, 98-105 IL-1 and, release, 327-332

synthesis inhibition, 277-283 IL-6 release from, 327-332 IL-10 effects in, 366-370 LPS and, effects, 277-283

priming, 327-332 murine peritoneal, 327-332 prostaglandin effects in, 327-332 tenidap effects on, 277-283 thioglycolate priming of, 327-332 TNF-o and, release, 327-332

stimulation, 12-16 zymosan effects on, 277-283

Major histocompatibility complex (MHC), class I, 35-41 epithelial cells and, 543-549 IL-2 receptor and, 35-41 IL-4 receptor and, 35-41 immunosuppression and, 6 responder cell restriction by, 6

Major histocompatibility complex (MHC), class I (Continued) TGF-l3 effect on, 543-549

MCP-1. See Monocyte chemotacticprotein-1 (MCP-1). Mesangial cells, angiotensin effects in, 131-133

calcium uptake by, 131-133 DNA synthesis in, 131-133 IL-1 growth inhibition in, 131-133 nicardipine effects in, 131-133

Metalloproteases, tissue inhibitor of, 231 Metamorphosis, T cell circumvention in, 28-33,30(t) Microtubules, cell motility and, 299-309

epithelial cell, 299-309 scatter factor effects on, 299-309

Minor histocompatibility antigens (mha), immunosuppression and, 5-10

MIP-1. See Macrophage inj?amrnatoryprotein-1 (MIP-1). Mitomycin C, IgA secretion and, 107-115 Mixed lymphocyte response, splenocytes and, 28-33,30(t)

thymus-replacing factor and, 28-33,30(t) Monkey, IL-8 of, 21-26 Monoclonal antibodies, IL-l and, 117-123

IL-2 and, 54-58 IL-3 and, 562-566 IL-4 and, 562-566 immunoassay using, 562-566 recombinant antigens and, 562-566

Monocyte chemotactic protein-l (MCP-l), 170-180 alternative names for, 166(t) amino acid sequence of, 166(t), 168(f) arthritis role of, 178-179 atherosclerosis role of, 178 cells expressing, 175(t), 179(f) chromosome 17 and, 172(f) isolation of, 167(f), 170 physiological role of, 175-180, 179(f) regulatory elements for, 173-174,175(t) structure of, 168(f), 172(f) T cells and, 174(f), 179(f) tumor cells secreting, 177-178

Monocyte chemotactic protein-l (MCP-1) gene, chromosome 17 and, 172(f)

structure of, 172(f) Monocytes, concanavalin effect on, 231-238

cytokine regulation iof, 531-538,532(f) gelatinase production by, 231-238 HIV replication and, 531-538,532(f) IL-ll3 and, effects, 231-238

production, 240-245 LPS and, effects, 231-238

stimulation, 568-574 myeloid progenitor of, 60-69 phorbol ester effect on, 231-238 protease secretion by, 231-238 psoriasis role of, 311-320 TNF release by, 568-574

Mononuclear cells (MNC), arthritis role of, 98-105 chronic fatigue syndrome effects in, 292-297 eosinophil differentiation of, 350-358 hypoxia effect on, 189-192 IL-1 synthesis by, 568-574 IL-la production by, 189-192 IL-ll3 production by, 189-192 IL-2 secreted by, 54-58 IL-6 induction and, 292-297 separation of, 296 septic shock role of, 568-574

646 I Subject index CYTOKINE, Vol. 3, No. 6 (November 1991: 638-648)

Mononuclear cells (MNC), arthritis role of (Continued) TGF-p increase and, 292-297 TNF production by, 189-192 TNF synthesis by, 568-574 TNF-cx induction and, 292-297 umbilical cord, 3.50-358

Motility. See Cellmotility. Mouse, IL-8 of, 21-26 Mucosa, B cells of, 107-115

IgA secretion and, 543-549 Peyer’s patches of, 107-115

Myeloid cells, 60-69 cytokine responsiveness of, 60-69 IL-la gene vector in, 60-69 IL-3 regulation of, 60-69

Myeloleukemic cells. See Leukemia cells. Ml cells, 83-90

Nephritis, autoimmune, TNF-(Y role in, 551-560 Neutrophil-activating peptide-l (NAP-l), cross-species potency of,

21-26 cyclosporin A non-effect on, 311-320 IL-8 relation to, 311 LPS induction of, 311-320 monocyte secretion of, 311-320

Neutrophil-activating peptide- (NAP-2), CTAP-III and, 311-320 IL-8 relation to, 311 neutrophil induction of, 311-320 precursor conversion to, 311-320 protease action and, 311-320

Neutrophils, chemotactic protein for, 21-26 elastase release by, 12 NAP-2 induction by, 311-320 proteases of, 12,311-320 psoriasis role of, 311-320 TNF-a stimulation of, 12-16

NF-KB factor, calcium ion non-effect on, 257-264 HIV transcription and, 536-537 IL-1 activation of, 372-378 pH effects and, 257-264 phorbol ester activation of, 257-264,372-378 protein kinase non-effect on, 257-264 serum amyloid A gene and, 380-387 TNF activation of, 372-378 TNF-o( activation of, 257-264

Nicardipine, IL-l effects and, 131-133 mesangial cells and, 131-133

Nonsteroidal anti-inflammatory drugs, bone Ca release and, 141-147

Osteoclasts, bone resorption and, 421-426 GM-CSF effects on, 421-426 M-CSF effects on, 421-426

Oxygen. See also Hypoxia consumption, IL-6 and, l-3,2t inflammation effects and, 189-192

Pancreas, islet cells of, 117-123 Pancreatitis, mild, 13, 13(t), 14

mortality in, 12-16 severe, 13,13(t), 14 TNF-ol and, 12-16

Parathyroid hormone, bone resorption and, 421-426 Particle concentration immunofluorescence assay, 17-20

IL-6 receptors measured in, 17-20 Parturition, IL-6 levels in, 155-162 Peanut agglutinin, B-cell populations and, 107-115 Pertussis toxin, IL-l stimulation and, 42-51

IL-2 secretion and, 42-51

Pertussis toxin, IL-l stimulation and, 42-51 (Continued) Peyer’s patches, B-cell differentiation and, 107-115

germinal centers of, 107-115 Phorbol esters, carcinoma cell effects of, 212-222

gelatinase induction by, 231-238 HIV and, enhancer, 372-378

replication, 531-538,537(f) hypoxia potentiation and, 189-192 IL-l synergism with, 42-51 IL-6 synergism with, 212-222 monocytes stimulated with, 231-235 NF-KB activation by, 372-378 staurosporine block of, 220

Pig, IL-8 of, 21-26 Plasma cells, helper T cells and, 107-115

IgA production and, 107-115 production of, 107-115

Plasmids, IL-5 production method using, 224-229 Platelet factor 4 (PF4), 165 Platelets, CTAP-III derived from, 311-320

NAP-2 formation and, 311-320 Polymerase chain reaction (PCR), interleukin-5 (IL-5) gene and,

72-80 intracellular cytokine detection and, 184-187

Prealbumin, inflammation and, 619-625 insulin and, 619~@5

Pregnancy, IL-6 levels in, 155-162 Progenitor cells, bone marrow and, 60-69 Prostaglandins, behavioral effects and, 333-337

bone resorption and, 421-426 GM-CSF and, 421-426 IFN-y effects and, 98-105 IL-l release and, 327-332 IL-la and, effects, 333-337

stimulation, 42-51 IL-16 stimulation of, 141-147 IL-6 release and, 327-332 infusion of, 333-337 macrophage cytokines and, 327-332 measurement of, 51 piroxicam inhibition of, 333-337 TNF release and, 568-574 TNF-ol release and, 327-332

Proteases, metallo-, 231 NAP-2 production role of, 311-320 tissue inhibitor of, 231

Protein kinase A (PKA), NF-KB factor and, 257-264 Protein kinase B (PKB), NF-KB factor and, 257-264 Protein kinase C (PKC), HIV transcription and, 536-537,537(f)

IL-l stimulation and, 42-51 IL-2 induction and, 42-51

Proteinases, IL-lp induction of, 231-238 inhibitors for, 13

elastase complex with, 13 tissue, 231-238

monocyte production of, 231-238 Proteins, acute phase, 619-625

IL-6 and, 619-625 insulin modulation of, 619-625

hybrid, antibody production and, 134-139 IFN-y/IL-la, 134-139 IFN-y/IL-lP, 134-139 IL-la antibodies and, 134-139 preparation of, 138

IL-6 and, 1-3,2(t), 619-625 Proteoglycans, cartilage loss of, 246-249

inflammation and, 246-249

Subject index / 647

Psoriasis, monocytes and, 311-320 NAP-l in, 311-320 neutrophils and, 311-320

Rabbit, IL-8 of, 21-26 Radiolabeling, IL-1 receptor antagonist, 411-412

IL-lru, 411-412 RANTES, 171-180

alternative names of, 166(t) amino acid sequence of, 168(f) arthritis role of, 178-179 atherosclerosis role of, 178 cells expressing, 175(t), 179(f) chemotactic effect of, 176(f) definition of, 166 isolation of, 167(f) monocytic cells and, 175(t) physiological role of, 175-180,179(f) proinflammatory action of, 176,176(f) regulatory elements for, 173-174,175(t) review of, 165-180 T cells and, 174(f), 175(t)-177(f) tumor cells secreting, 177-178

Rat, IL-8 of, 21-26 Receptors, antagonists and, 407-412

binding by, 407-412 Resistance (vascular), IL-6 effects and, 1-3,2(t) Retinol binding protein, inflammation and, 619-625

insulin and, 619-625 Retroviral vectors, bone marrow infection with, 60-69

IL-la gene in, 60-69 IL-5 gene and, 72-80 myeloid cell line and, 60-69

Reverse hemolytic plaque analysis (RHPA), 185(t), 186-187 Reviews, HIV regulation, 531-538

IL-lo, 366-370 RANTES, 165-180

Rheumatoid arthritis, synovial cells of, IL-1 binding and, 407-412 mRNA, measurement of, 184-187

single-cell cytokine detection and, 184-187

Sarcoma cells, cytokine induction in, 284-290 IL-1B effects on, 284-290 lithium chloride effects and, 284-290 TNF effects on, 284-290

Scatter factor (SF), cell motility and, 299-309 cytoskeleton effects of, 299-309 epithelial cells and, 299-309

Secretory component (SC), epithelial cells and, 543-549 IgA secretion and, 543-549 mucosal surfaces and, 543-549 TGF-B effects on, 543-549

Sepsis. See also Lipopolysaccharides (LPS). IL-1 effects and, 568-574 IL-6 release and, 1-3,2(t) macrophage stimulation in, 12-16,14 neutrophil stimulation in, 12-16,14 pancreatitis as, 12-16,14 shock produced by, 568-574 taurolidine effects and, 568-574 temperature effects and, 389-396 TNF effects and, 568-574

Serum amyloid A, gene transcription and, 380-387 IL-1 mediation and, 380-387 NF-KB and, 380-387

Shock, IL-6 release and, 1-3,2(t)

SIG molecules, definition of, 166 SIS molecules, definition of, 166 Species cross-reactivity, IL-8 and, 21-26

NAP-1 and, 21-26 Spleen cells, antibody production in, 141-147

frog, 28-33,30(t) IL-1B stimulation of, 141-147 IL-3 production in, 6 metamorphic, 28-33,30(t) myeloma hybrid with, 134-139 plaque forming, 141-147 T cell circumvention and, 28-33, 30(t)

Staining, cytokine detection and, 185(t), 186 Staphylococcal infections, taurolidine protection and, 568-574

toxic shock and, 568-574 Staurosporine, phorbol ester block by, 220 Streptavidin, fluorescein-labeled, IL-3 binding marked by, 414-419 Streptococcal cell wall fragments, arthritis produced by, 98-105 Stress fibers, cell motility and, 299-309 Suppressor T cells, immunosuppression and, 5-10 Synovium, 407

cells of, fibroblast, 269-275 IL-lo receptor antagonist and, 407-412 IL-lol receptor on, 407-412

IFN-a effects in, 98-105 IFN-B effects in, 98-105 IFN-?/ effects in, 98-105 IL-1 effects in, 246-249 inflammation of, 246-249

T cells. See also Cytotoxic Tcells; Helper T cells. activation mechanisms of, 35-41 antigen receptors on, a,598606

f3,598-606 6,598-606 y, 598-606 yS heterodimer, 598-606 IL-2 effect on, 598606

blastogenesis inhibitor for, 609-617 CD molecules on, 598-606 circumvention of, 28-33,30(t) HIV expression and, 531-538,532(f) IL-l effects and, 42-51,372-378 IL-la receptors of, 125-130 IL-2 and, effects, 584-591

receptor, 35-41 secretion, 42-51 stimulation, 593-597

IL-2Rcl expression by, 584-591 IL-2RB expression by, 584-591 IL-4 and, effects, 584-591

receptor, 35-41 stimulation, 593-597

IL-5 effects on, 584-591 immunosuppression and, 5-10 MCP-1 and, 174(f), 179(f) MHC class I molecules of, 35-41 MIP-la and, 174(f), 177(f), 179(f) MIP-1B and, 174(f), 177(f), 179(f) NF-KB and, 257-264,372-378 phorbol ester effects on, 257-264,372-378 proliferative cycle of, 593-597

inhibitor for, 609-617 RANTES and, 174(f), 175(t)-177(f) thymidine incorporation and, 593-597 thymocyte origin of, 598-606 TNF-o( effects and, 257-264,372.378

648 / Subject index CYTOKINE, Vol. 3, No. 6 (November 1991: 638-648)

Talin, cell motility and, 299-309 (Continued) Talin, cell motility and, 299-309 Taurolidine, IL-1 synthesis inhibited by, 568-574

sepsis effects inhibited by, 568-574 taurine and, 568-574 TNF synthesis inhibited by, 568-574

Temperature. See also Fever. febrile response and, 389-396 hypothalamus and, 195-197 IL-2 and, expression, 389-396

secretion, 389-396 IL-6 and, 1-3,2(t) T-cell proliferation and, 389-396

Tenidap, antiarthritic effects of, 277-283 IL-l synthesis inhibited by, 277-283 leukotriene synthesis and, 277-283 macrophage response to, 277-283 prostaglandin synthesis and, 277-283

Thioglycolate, macrophage priming with, 327-332 Thirst, IL-la and, 333-337 Thymocytes, T-cell-antigen receptors and, 598-606 Thymoma cells, 42-51

conditioned media containing, 350-358 eosinophil differentiation and, 350-358 IL-5 produced by, 350-358

Thymus-replacing factor, spleen production of, 28-33,30(t) Thyroid cells, IL-la receptors of, 125-130

IL-l/3 enhancement in, 345-348 IL-6 production by, 345-348 TSH enhancement in, 345-348

Thyroid-stimulating hormone (TSH), IL-1B synergy with, 345-348 IL-6 production and, 345-348

Tissue inhibitor of metalloproteases (TIMP), 231 Toxic shock syndrome, taurolidine inhibition and, 568-574 Transferrin, inflammation and, 619-625

insulin and, 619-625 Transforming growth factor-d (TGF-a), carcinoma cells and, 212-

222 Transforming growth factor-l3 (TGF-B), HIV expression and, 534-

535 IL-6 not induced by, 269-275

Transforming growth factor-p, (TGF-/3,), carcinoma cells and, 212- 222

chronic fatigue syndrome and, 292-297 epithelial cells and, 543-549 immunoglobulin binding and, 543-549 MHC antigens and, 543-549 secretory component expression and, 543-549

Tubulin, cell motility and, 299-309 B-Tubulin, temperature effects and, 389-396 Tumor cells, endotoxin-induced, 398-405

extracellular matrix of, 250-255 fibronectin and, 250-255 ganglioside expression by, 250-255 IFN-a response and, 398-405 IFN-B response and, 398-405 IL-l response and, 398-405 IL-6 response and, 398-405 intradermal implantation of, 398-405 MCP-1 secreted by, 177(f), 177-178,179(f) motility of, 250-255 RANTES secreted by, 177(f), 177-178,179(f) TNF resistance in, 250-255 transglutaminase activity in, 250-255

Tumor necrosis factor (TNF), cell resistance to, 250-255 endotoxin-induced, 398-405 evolutionary role of, 636-637

Tumor necrosis factor (TNF), cell resistance to (Continued) fibroblast response to, 269-275 fibronectin and, 250-255 gangliosides and, 250-255 hybridoma cell response to, 284-290 hypoxia potentiation of, 189-192 IL-6 and, induction, 269-275

non-effect, l-3 insulin secretion and, 117-123 islet cell effects of, 117-123 lithium chloride and, 284-290 LPS stimulation and, 576-582 meeting report on, 361-363 monocyte release of, 568-574 mononuclear cell synthesis of, 568-574 prostaglandins and, 568-574 ribbon representation of, 362(f) sarcoma cell response to, 284-290 septic shock role of, 568-574 taurolidine inhibition of, 568-574 tumor cell implantation and, 398-405

Tumor necrosis factor (TNF) gene, polymorphism in, 555-560 Tumor necrosis factor receptor (TNFR), hepatocyte expression of,

149-153 IL-6 enhancement and, 149-153

Tumor necrosis factor-a (TNF-(w), arthritis and, 266-267 chronic fatigue syndrome and, 292-297 evolutionary role of, 636-637

fos gene and, 372-378 HIV enhancer and, 372-378 HIV expression and, 531-538,532(f), 536(f) IL-2 enhancer and, 372-378 jun gene and, 372-378 lupus disease and, 551-560 macrophages and, production, 551-560

release, 327-332 stimulation, 12-16

neutrophil stimulation by, 12-16 NF-KB activation by, 257-264,372-378 pancreatitis and, 12-16 prostaglandin regulation of, 327-332 T cell response to, 257-264

Tumor necrosis factor-p (TNF-B), evolutionary role of, 636-637 Tyrosine kinase, IL-2 receptor complex as, 428-437

Umbilical cord, mononuclear cells from, 350-358 Uterine infection, IL-6 levels in, 155-162

Vectors, IL-5 production and, 224-229 plasmid, 224-229 recombinant baculovirus, 224-229

Vimentin filaments, cell motility and, 299-309 Vinculin, cell motility and, 299-309 Viruses, 92

HIV. See Human immunodejkiency virus (HN). IL-la encoded by, 92-96 influenza, 92-96 recombinant, 92-96 vaccinia, 92-96

Vitamin D, bone resorption and, 421-426

Water drinking, IL-la and, 333-337 Weight loss, IL-la and, 333-337

Zinc, IL-6 effects and, 199-202 Zymosan, IL-1 induction by, 277-283

macrophage response to, 277-283